Company intelligence / Profile preview

Tricida, Inc.

South San Francisco, California, USAasn.tricida.com ↗

Ownership: Private
Employees: ~57
Development stage: Phase 3

Overview

Tricida developed veverimer (TRC101), a nonabsorbed oral polymer designed to treat metabolic acidosis in CKD patients. Veverimer completed Phase III clinical trials and an NDA submission but did not receive FDA approval. The company subsequently filed for bankruptcy and ceased operations in June 2023

Therapeutic areas: Nephrology
Modalities: Small molecules/polymer-based therapeutics
Industry: Biotech

Drug pipeline

1 asset

veverimer

Beyond the preview

Go deeper on Tricida, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tricida, Inc..

Explore the full profile